About: Pharmacokinetic characterization of amrubicin cardiac safety in an ex vivo human myocardial strip model. II. Amrubicin shows metabolic advantages over doxorubicin and epirubicin

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Pharmacokinetic characterization of amrubicin cardiac safety in an ex vivo human myocardial strip model. II. Amrubicin shows metabolic advantages over doxorubicin and epirubicin Goto Sponge NotDistinct Permalink

An Entity of Type : wikibase:Item, within Data Space : wikidata.demo.openlinksw.com associated with source document(s)

scientific article published on 15 February 2012

Attributes	Values
rdf:type	Item
description	wetenschappelijk artikel (nl) article scientifique publié en 2012 (fr) наукова стаття, опублікована в лютому 2012 (uk) scientific article published on 15 February 2012 (en) artículu científicu espublizáu en febreru de 2012 (ast)
publication date	wds:Q83455932-FF04B1D5-03D5-4E99-B1E7-776FC2E587F8
publication date	2012-02-15 00:00:00Z (xsd:dateTime)
author name string	wds:Q83455932-22A95139-A3AF-40F9-A224-63E73B0066A2 wds:Q83455932-8E53B2FF-F4BF-4316-BC14-1D6D9680FD99 wds:Q83455932-C07B0F1F-7242-4BB3-B1A5-0B53F672943B wds:Q83455932-F8E3DFFD-99CF-4CCE-8971-9AA261E18056
author name string	Sharon L Aukerman Victoria Sung Odalys Gonzalez Paz Sekhar Surapaneni
rdfs:label	Pharmacokinetic characterization of amrubicin cardiac safety in an ex vivo human myocardial strip model. II. Amrubicin shows metabolic advantages over doxorubicin and epirubicin (en) Pharmacokinetic characterization of amrubicin cardiac safety in an ex vivo human myocardial strip model. II. Amrubicin shows metabolic advantages over doxorubicin and epirubicin (nl)
skos:prefLabel	Pharmacokinetic characterization of amrubicin cardiac safety in an ex vivo human myocardial strip model. II. Amrubicin shows metabolic advantages over doxorubicin and epirubicin (en) Pharmacokinetic characterization of amrubicin cardiac safety in an ex vivo human myocardial strip model. II. Amrubicin shows metabolic advantages over doxorubicin and epirubicin (nl)
name	Pharmacokinetic characterization of amrubicin cardiac safety in an ex vivo human myocardial strip model. II. Amrubicin shows metabolic advantages over doxorubicin and epirubicin (en) Pharmacokinetic characterization of amrubicin cardiac safety in an ex vivo human myocardial strip model. II. Amrubicin shows metabolic advantages over doxorubicin and epirubicin (nl)
author	wds:Q83455932-446F3CE9-B19B-4A93-9D82-36B498313704 wds:Q83455932-4DC097EF-8497-4650-BC54-27B217277BDA wds:Q83455932-DB55B57F-8BA4-4191-8DAB-B644936E5F9F wds:Q83455932-DF9BD019-D119-4572-A3A0-C3B74FD06EB7 wds:Q83455932-E75AB217-7872-413A-8650-9DCB26DB8869
author	Elvio Covino Giorgio Minotti Massimo Chello Pierantonio Menna Emanuela Salvatorelli
title	wds:Q83455932-90D09A93-120E-4A92-A9CD-3FF3D941CDEF
title	Pharmacokinetic characterization of amrubicin cardiac safety in an ex vivo human myocardial strip model. II. Amrubicin shows metabolic advantages over doxorubicin and epirubicin (en)
page(s)	wds:Q83455932-0E9130B8-1EC9-4C7B-A948-52DB6555CA17
page(s)	474-483
instance of	wds:Q83455932-B0B2BAF9-B475-4972-B914-82A96705A445
instance of	scholarly article
main subject	wds:Q83455932-5B2271DE-9D44-4724-8539-035D6A54FE48
main subject	wd:Q18936
PubMed ID	wds:Q83455932-140F5EB5-E875-4F40-B6A8-7D8B13952FD8
PubMed ID	http://rdf.ncbi.nlm.nih.gov/pubchem/reference/22338034
PubMed ID	22338034
published in	wds:Q83455932-98F540EA-8F63-4C38-8B69-9BB7BB7AF566
published in	Journal of Pharmacology and Experimental Therapeutics
issue	wds:Q83455932-797F63F6-9AB2-4B81-8030-5C3981BEB88D
volume	wds:Q83455932-E1028D5B-2A80-4A77-96F2-E64C7C1B4020
issue	2
volume	341
DOI	wds:Q83455932-81087654-FC37-498C-8EDB-9543A39FBE2E
DOI	http://dx.doi.org/10.1124/JPET.111.190264
DOI	10.1124/JPET.111.190264
is about of	https://www.wikidata.org/wiki/Special:EntityData/Q83455932
is cites work of	Protective effect of 23-hydroxybetulinic acid on doxorubicin-induced cardiotoxicity: a correlation with the inhibition of carbonyl reductase-mediated metabolism Influence of mitochondrion-toxic agents on the cardiovascular system Systemic treatment in advanced soft tissue sarcoma: what is standard, what is new. Phase II study of amrubicin (SM-5887), a synthetic 9-aminoanthracycline, as first line treatment in patients with metastatic or unresectable soft tissue sarcoma: durable response in myxoid liposarcoma with TLS-CHOP translocation. Chemotherapeutic Drugs and Mitochondrial Dysfunction: Focus on Doxorubicin, Trastuzumab, and Sunitinib. C609T Polymorphism of NADPH Quinone Oxidoreductase 1 Correlates Clinical Hematological Toxicities in Lung Cancer Patients Treated with Amrubicin Mitochondria-Targeting Small Molecules Effectively Prevent Cardiotoxicity Induced by Doxorubicin Amrubicin: potential in combination with cisplatin or carboplatin to treat small-cell lung cancer Interaction Effects between Doxorubicin and Hernandezine on the Pharmacokinetics by Liquid Chromatography Coupled with Mass Spectrometry
is cites work of	wds:Q28606782-F3527F5A-84D2-43C1-B0F4-B243EF91C426 wds:Q38137648-2D271A6E-D779-4AFB-996B-20D102AF1C95 wds:Q36622902-AFFF698D-6A24-4269-83EB-801E9AF6A34F wds:Q47631238-1AD174F7-DC24-44FA-B00E-85F2BD8293FB wds:Q89158159-CF4A61A5-0E0F-4F0F-8976-46F266AF1A3C wds:Q38129050-4042BE74-E2CF-40CC-BBD1-36CC254A6251 wds:Q55222160-F7A9EF09-42E2-4BE1-AFC4-95F8F0F9C65E wds:Q90613710-FADA66F5-B9E5-4E15-96D1-8DA5B3C13109 wds:Q36389964-821C5626-51A9-44A1-8425-778229E44386

Faceted Search & Find service v1.16.117 as of May 05 2024

Alternative Linked Data Documents: ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3239 as of May 5 2024, on Linux (x86_64-centos_6-linux-gnu), Single-Server Edition (378 GB total memory, 183 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software